CAMBRIDGE, Mass., Nov. 17, 2014 /PRNewswire/ -- Seres Health, Inc., a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that Eric Shaff has joined Seres as its Chief Financial Officer. Mr. Shaff will provide strategic financial guidance for Seres and manage the overall finances of the company.
Prior to joining Seres, Mr. Shaff was Vice President, Corporate Finance at Momenta Pharmaceuticals where he helped oversee Momenta's financial management including planning, financial control, procurement and investor relations. Mr. Shaff brings over 15 years of corporate biotech finance and development experience to Seres. Prior to Momenta, Mr. Shaff was Vice President, Finance of Genzyme's Rare Genetic Disease Division and held several positions at Genzyme in Business Unit Finance and Corporate Finance as well as Corporate Development. Previously, Mr. Shaff worked in Corporate Finance at Pfizer, and worked in investment banking for Broadview International (now Jefferies Broadview).
"Seres' innovative Microbiome Therapeutics platform and rapidly expanding pipeline of therapeutics have the potential to make a significant positive impact in treating patients with microbiome-driven diseases," said Mr. Shaff. "I am thrilled to be joining Seres at such an exciting time and I look forward to working with the leadership team on the company's next phase of growth."
"We are very pleased to have Eric on the Seres team," said Dr. Roger J. Pomerantz, President, CEO and Chairman of Seres Health. "His experience and contributions will be extremely valuable as we further advance SER-109, our lead Ecobiotic® microbial therapeutic and accelerate Seres' progress towards commercialization."
Mr. Shaff earned his BA from the University of Pennsylvania in Political Science and Economics. He earned his MBA from the Johnson Graduate School of Management at Cornell University with a concentration in Finance.
About Seres Health
Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by the Flagship Ventures innovation foundry, VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research alliance with Mayo Clinic and has received over $20 million in funding to date. For more information, please visit www.sereshealth.com.
For Seres Health: Emily Rossi
SOURCE Seres Health